openPR Logo
Press release

US Cancer Generics Market Outlook 2022 Report

05-07-2018 06:07 AM CET | Health & Medicine

Press release from: Kuick Resarch

“US Cancer Generics Market Outlook 2022” report highlights:

* Introduction to Cancer Generics
* US Generic Drugs Legislature
* US Health Insurance Scenario and Cancer
* Aspects of Branded and Non-Branded Generics
* US Cancer Generics Market Overview

Download Report Sample Weblink:

https://www.kuickresearch.com/report-us-cancer-generics-market-outlook-2022.php

For Report Sample Contact: neeraj@kuickresearch.com

Table of Contents

Cancer Generics: A Modest Regimen
1.1 Introduction to Cancer Generics
1.2 Why There Exist is Need for Generic Forms?
1.3 Supremacy of Cancer Generic Drugs
1.3.1 Cost
1.3.2 Quality and Safety
1.3.3 Large Number of Manufacturer
1.3.4 Approved by FDA
1.3.5 Concerns in Cancer Generic Medication

US Generic Drugs Legislature
2.1 Hatch-Waxman Act, 1984
2.2 The Generic Drugs Chronological Disgrace

Trail towards Patenting of Cancer Generic Drugs
3.1 US Generic Pharmaceutical Regulation
3.2 Patenting Wars of Cancer Generics in US

Economic Burden of Prescription Drugs in US
4.1 High Cost of Cancer Drugs
4.2 Healthcare Savings by Virtue of Generics

Cancer Generic Drugs: Still Overpriced in US Market
5.1 Innovation is Meaningless if Nobody can Afford It
5.2 Why US Contends More in Generics?

US Health Insurance Scenario and Cancer
6.1 Provisions for Cancer Drug Coverage
6.2 Private Health Insurance Options
6.3 Government Funded Insurance

Aspects of Branded and Non-Branded Generics
7.1 Debut of Authorized Generics in Market
7.2 Anti-Authorized Generic Legislation

Generics in Oncology World
8.1 Anti-Cancer Targeted Therapy Drugs
8.2 Status of Generics in Monoclonal Antibodies
8.3 Crusade of Small Molecule Inhibitor towards Generics

FDA Approved Anti-Cancer Generics in US
9.1 Taxotere (Generic Docetaxel)
9.2 Imatinib (Generic Glivec)
9.3 Sorafinib ( Generics Nexavar)

US Cancer Generics Market Overview
10.1 US Cancer Generics Market Introduction
10.2 Europe Generics Market Contrary to US
10.3 Asia Generics Market Contrary to US

Cancer Generics Drug Market Dynamics
11.1 Accelerative Parameters
11.1.1 Expiration of Patents
11.1.2 Unaffordability of Cancer Drugs
11.1.3 Cost Containment by Government
11.1.4 Generic Drug User Fee Amendments (2012)
11.1.5 High Cancer Risk and Aging Population of US
11.2 Pitfalls Confronted by Generic Industry

US Cancer Generics Market Future Prospect

Figure 1-1: US - Savings through Generic Drug usage (US$ Billion), 2010-2015
Figure 1-2: Zofran- Price of Branded and Generic Pill (US$)
Figure 1-3: Illustration of Pros and Cons of Generic Drugs
Figure 2-1: Interests of Brand drug and Generic Drug Industry over Hatch-Waxman Act
Figure 3-1: Major Exclusivity under the NDA Statutory Requirements
Figure 3-2: Demonstration of Bringing Generic Drug into Market
Figure 3-3: US - FDA Rules for Generics Production
Figure 4-1: Branded V/S Generic Prescription Drug Revenues (2005-2015)
Figure 4-2: US andndash; Expected Cost Savings through Generics in Cancer Therapy (US$ Billion), 2016-2022
Figure 4-3: US - Potential Cost Saving Across Biologics in
Figure 5-1: US - Representation of Generic Cost of Gleevac
Figure 6-1: Distribution of Medicare Savings in FY2016 Budget
Figure 6-2: Cost Sharing of Generic Drug in Medicare Part D Coverage Gap (%), 2015-2020
Figure 6-3: Various Medicare Beneficiaries Provided by US Government
Figure 6-4: US - Share of Medicare and Self Payment for Generics Drug (%)
Figure 7-1: Illustration of the Profits Earned During the 180-Day Exclusivity
Figure 7-2: Strategies for Launching Authorized Generics in Market
Figure 8-1: US - Proportion of Branded and Generic Drug Revenues (%), 2010-2015
Figure 8-2: FDA Approved Monoclonal Antibodies in Cancer Therapeutics
Figure 8-3: Development Cost of Generics v/s Biosimilar
Figure 9-1: Cost Comparison of Gleevac in Branded and Generic Versions
Figure 9-2: Naxawar Price Difference in Generic and Branded Version
Figure 10-1: Global - Top Generics Manufacturers Based on Revenues (US$ Billion), 2015
Figure 10-2: US andndash; Generics Drug Market Opportunity (US$ Billion). 2016-2022
Figure 10-3: US - Savings through Generic Drug Usage (US$ Billion), 2017-2022
Figure 10-4: US - Share of Leading Generic Companies
Figure 11-1: Major Accelerative Parameters for the Growth of Generic Market
Figure 11-2: Current Challenges Faced by Generic Pharmaceutical

Kuick Research is a market research and analytics company that provides targeted information for critical decisions at business, product and service levels. We are quick, predictive and known by the recommendations we have made in the past. Our result-oriented research methodology offers understanding of multiple issues in a short period of time and gives us the capability to keep you full with loads of practical ideas. By translating research answers into strategic insight and direction, we not only rate the success potential of your products and/or services, but also help you identify the opportunities for growth in new demographies and find ways to beat competition.

Neeraj Chawla
neeraj@kuickresearch.com
KuicK Research
L29 - L34, First Floor
Block L,Connaught Place
New Delhi-110001
+91-11-47067990

This release was published on openPR.

Permanent link to this press release:

Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.

You can edit or delete your press release US Cancer Generics Market Outlook 2022 Report here

News-ID: 1040659 • Views:

More Releases from Kuick Resarch

Lumakras Drug Clinical Insight and Sales Forecast 2026
Lumakras Drug Clinical Insight and Sales Forecast 2026
"Lumakras Drug Clinical Insight and Sales Forecast 2026" Report Highlights: * NSCLC Targeting Lumakras Market Opportunity (US$ Million) * Colorectal Cancer Targeting Lumakras Market Opportunity (US$ Million) * Pharmacokinetics of Lumakras (Sotorasib) * Dosage, Patent and Price Analysis * Lumakras Ongoing Clinical Trials * Global KRAS Protein Inhibitors Clinical Trials Download Report: https://www.kuickresearch.com/report-lumakras-sotorasib-sales-forecast-fda-approved-kras-inhibitor-clinical-trials-non-small-cell-lung-cancer-nslc-g12c-mutation-c30h30f2n6o3-ras-gtpase The rising burden of cancer and the increasing cancer mortality rates possesses an unmet need for the development of novel therapies in the management
Global EZH2 Inhibitor Market Opportunity, Sales and Clinical Trials Insight 2026
Global EZH2 Inhibitor Market Opportunity, Sales and Clinical Trials Insight 2026
"Global EZH2 Inhibitor Market Opportunity, Sales and Clinical Trials Insight 2026" Report Highlights: * Global EZH2 Inhibitor Market Opportunity > US$ 1.2 Billion by 2026 * Tazverik (Tazemetostat) First Approved EZH2 Inhibitor Drug * Dosage, Price and Sales Analysis of Tazverik * Tazverik Sales Opportunity > US$ 900 Million by 2026 * Tazverik Sales Forecast 2021 Till 2026 * EZH2 Inhibitor Clinical Pipeline Overview By Company, Indication and Phase * EZH2 Inhibitor in Clinical Trials: 7 Drugs Download
Global Bispecific Antibody Market Opportunity, Drug Sales, Price and Clinical Trials Insight 2028
Global Bispecific Antibody Market Opportunity, Drug Sales, Price and Clinical Tr …
"Global Bispecific Antibody Market Opportunity, Drug Sales, Price and Clinical Trials Insight 2028" Report Highlights: * Global Bispecific Antibody Market Opportunity: > US$ 20 Billion * Global Bispecific Antibody Market Growth Rate: 100% CAGR (2016 -2021) * Approved Bispecific Antibodies In Market: 4 Antibodies * Detailed Market Sales and Trends Insight Till 2028 * Quarterly and Yearly Sales Insight Of Approved Antibodies Till Q1 2022 * Global and Regional Market Analysis * Approved Drug Sales
Global Fibroblast Growth Factor Receptor Inhibitor Drug Market Opportunity and Clinical Trials Insight 2026
Global Fibroblast Growth Factor Receptor Inhibitor Drug Market Opportunity and C …
"Global Fibroblast Growth Factor Receptor Inhibitor Drug Market Opportunity and Clinical Trials Insight 2026" Report Highlights: * Global FGFR Inhibitors Market Opportunity: > USD 4 Billion by 2026 * Role of FGFR Inhibitors in Cancer Therapy * Global FGFR Market Assessment (US$) by Region and Cancer Type Clinical and Sales Insight on Approved FGFR Inhibitors: 3 (Belvesra, Pemazyre and Truseltiq) * Dosage and Drug Price Insight on Approved FGFR Inhibitors * Comprehensive Clinical Trials Insight

All 5 Releases


More Releases for Generic

Generic Injectables Market growth is attributed to the increasing demand for Onc …
According to Precision Business Insights (PBI), the latest report, the generic injectables market will be worth USD 22.0 billion in 2022, growing at an 11.0% CAGR from 2022 to 2028. The global generic injectables market is segmented into the following types: Product Type (Monoclonal Antibodies, Cytokines, Insulin, Peptide Hormones, Blood Factors, Immunoglobulins, Peptide Antibiotics, Vaccines, and Others), Indication (Diabetes, Cancer, Cardiovascular Diseases, Musculoskeletal, CNS, Infections, and Others), Distribution Channel (Hospital
A Demand On Generic Drugs Market And The Need To Push The Market Of Generic Drug …
Global Generic Drugs Market A generic drug is pharmaceutical drug, which is bio-equivalent to a branded drug in all forms such as route of administration, strength, dosage, quality, intended use and performance. Generic drugs are usually approved after patent expiration of patent drugs. Generic drugs are safe, effective and FDA approved. The global market is filled with 44% of generic drugs. The global generic drugs market is driven by the rise of
Generic Wellness Offers Special Discount on Generic Xenical for Fat Reduction !
This week a special offer is introduced by Generic Wellness for weight loss treatment with an oral drug called generic Xenical. The drug is an excellent weight loss treatment for all men and women above the age of 12. People who have taken this drug for weight loss have actually experienced the benefits like reduction of unwanted fat in the body. This is possible with generic Xenical because of the
Generic Drugs Market Trends 2025
Generic drugs market growth is buoyed by increasing number of expiries of patented drugs each year. According to the IMS data small-molecule products worth US$ 121 Bn are expected to lose patents in developed markets, such as U.S ad Europe between 2014 and 2018. The IMS also forecasts that biologic products valued at US$ 48 Bn are expected to lose patent protection over the next three years i.e from 2017
Generic Drugs Market - Global Competitive Analysis
Generic drugs market growth is buoyed by increasing number of expiries of patented drugs each year. According to the IMS data small-molecule products worth US$ 121 Bn are expected to lose patents in developed markets, such as U.S ad Europe between 2014 and 2018. The IMS also forecasts that biologic products valued at US$ 48 Bn are expected to lose patent protection over the next three years i.e from 2017
Generic Drug Market: Global Generic Drug Share to Reach USD 380.60 Billion by 20 …
Zion Market Research has published a new report titled “Generic Drug Market by Brand (Pure Generic and Branded Generic) for Central Nervous System (CNS), Cardiovascular, Dermatology, Oncology, Respiratory and Others Therapeutic Applications - Global Industry Perspective, Comprehensive Analysis and Forecast, 2015 – 2021”. According to the report, the global generic drug market accounted for around USD 200.20 billion in 2015 and is expected to reach approximately USD 380.60 billion by